Skip to main content

A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors.

Publication ,  Journal Article
Dowlati, A; Vlahovic, G; Natale, RB; Rasmussen, E; Singh, I; Hwang, YC; Rossi, J; Bass, MB; Friberg, G; Pickett, CA
Published in: Clin Cancer Res
September 15, 2016

PURPOSE: To assess the toxicity, pharmacokinetics, tumor vascular response, tumor response, and pharmacodynamics of AMG 780, a mAb designed to inhibit the interaction between angiopoietin-1 and -2 and the Tie2 receptor. EXPERIMENTAL DESIGN: This was a phase I dose-escalation study of patients with advanced solid tumors refractory to standard treatment without previous antiangiogenic treatment. AMG 780 was administered by intravenous infusion every 2 weeks in doses from 0.1 to 30 mg/kg. The primary endpoints were incidences of dose-limiting toxicity (DLT) and adverse events (AE), and pharmacokinetics. Secondary endpoints included tumor response, changes in tumor volume and vascularity, and anti-AMG 780 antibody formation. RESULTS: Forty-five patients were enrolled across nine dose cohorts. Three patients had DLTs (0.6, 10, and 30 mg/kg), none of which prevented dose escalation. At 30 mg/kg, no MTD was reached. Pharmacokinetics of AMG 780 were dose proportional; median terminal elimination half-life was 8 to 13 days. No anti-AMG 780 antibodies were detected. At week 5, 6 of 16 evaluable patients had a >20% decrease in volume transfer constant (K(trans)), suggesting reduced capillary blood flow/permeability. The most frequent AEs were hypoalbuminemia (33%), peripheral edema (29%), decreased appetite (27%), and fatigue (27%). Among 35 evaluable patients, none had an objective response; 8 achieved stable disease. CONCLUSIONS: AMG 780 could be administered at doses up to 30 mg/kg every 2 weeks in patients with advanced solid tumors. AMG 780 treatment resulted in tumor vascular effects in some patients. AEs were in line with toxicity associated with antiangiopoietin treatment. Clin Cancer Res; 22(18); 4574-84. ©2016 AACR.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

September 15, 2016

Volume

22

Issue

18

Start / End Page

4574 / 4584

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Oncology & Carcinogenesis
  • Neoplasms
  • Neoplasm Staging
  • Middle Aged
  • Male
  • Humans
  • Female
  • Drug Monitoring
  • Dose-Response Relationship, Drug
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dowlati, A., Vlahovic, G., Natale, R. B., Rasmussen, E., Singh, I., Hwang, Y. C., … Pickett, C. A. (2016). A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res, 22(18), 4574–4584. https://doi.org/10.1158/1078-0432.CCR-15-2145
Dowlati, Afshin, Gordana Vlahovic, Ronald B. Natale, Erik Rasmussen, Indrajeet Singh, Yuying C. Hwang, John Rossi, Michael B. Bass, Gregory Friberg, and Cheryl A. Pickett. “A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors.Clin Cancer Res 22, no. 18 (September 15, 2016): 4574–84. https://doi.org/10.1158/1078-0432.CCR-15-2145.
Dowlati A, Vlahovic G, Natale RB, Rasmussen E, Singh I, Hwang YC, et al. A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Sep 15;22(18):4574–84.
Dowlati, Afshin, et al. “A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors.Clin Cancer Res, vol. 22, no. 18, Sept. 2016, pp. 4574–84. Pubmed, doi:10.1158/1078-0432.CCR-15-2145.
Dowlati A, Vlahovic G, Natale RB, Rasmussen E, Singh I, Hwang YC, Rossi J, Bass MB, Friberg G, Pickett CA. A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Sep 15;22(18):4574–4584.

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

September 15, 2016

Volume

22

Issue

18

Start / End Page

4574 / 4584

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Oncology & Carcinogenesis
  • Neoplasms
  • Neoplasm Staging
  • Middle Aged
  • Male
  • Humans
  • Female
  • Drug Monitoring
  • Dose-Response Relationship, Drug